HOW CAN WE HELP YOU? Call 1-800-TRY-CHOP
ON-TRK
This study is now recruiting.
The goal of this observational study is to describe the safety and effectiveness of larotrectinib in patients with locally advanced or metastatic TRK fusion cancer for whom a decision to treat with larotrectinib has been made before enrollment.
This study will enroll participants with any tumors harboring the NTRK gene fusion including Soft Tissue Sarcomas, Central Nervous System, Melanoma, and Thyroid cancers.
Who Do I Contact?
If you are interested in participating in the study or want to learn more please contact our study team at CancerTrials [at] chop.edu or 267-425-5544.
Eligibility & Criteria
IRB #:
21-019458
Official Title:
ON-TRK: PrOspective Non-interventional study in patients with locally advanced or metastatic TRK fusion cancer treated with larotrectinib
Study Phase:
Not Applicable
Eligible Age Range:
0 - 99 Years
Gender:
All
Visit Criteria
As a participant in the research we:
- Will review your past medical records
- May ask you some questions about your medical history
Leader
